Established industry leaders and emerging innovators such as Adicet Bio, IN8Bio, Sanofi, Merck, LAVA Therapeutics, Takeda and Leucid Bio are driving the race to demonstrate the potential of Gamma Delta T Therapies as cytotoxic, off-the-shelf solid tumor therapies, spurred by early indications of clinical efficacy.

The 4th Gamma Delta T Therapies Summit returns to Boston this July as the ultimate Industry-focused forum to advance your Gamma Delta T research, spanning dedicated 2 tracks of content to maximize your Clinical & Product Optimization and Research & Translational Development. Join 150+ expert industry peers for 2 full days of sessions and a pre-conference workshop and deep-dive day, building on early clinical successes, highlighting process and engineering innovations and leveraging early clinical insights to cast the spotlight onto Gamma Delta T Therapies in the clinic.

To know more visit: https://ter.li/69o2yc